Your browser doesn't support javascript.
loading
International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19.
Börger, Verena; Weiss, Daniel J; Anderson, Johnathon D; Borràs, Francesc E; Bussolati, Benedetta; Carter, David R F; Dominici, Massimo; Falcón-Pérez, Juan M; Gimona, Mario; Hill, Andrew F; Hoffman, Andrew M; de Kleijn, Dominique; Levine, Bruce L; Lim, Rebecca; Lötvall, Jan; Mitsialis, S Alex; Monguió-Tortajada, Marta; Muraca, Maurizio; Nieuwland, Rienk; Nowocin, Anna; O'Driscoll, Lorraine; Ortiz, Luis A; Phinney, Donald G; Reischl, Ilona; Rohde, Eva; Sanzenbacher, Ralf; Théry, Clotilde; Toh, Wei Seong; Witwer, Kenneth W; Lim, Sai Kiang; Giebel, Bernd.
Afiliação
  • Börger V; Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
  • Weiss DJ; Department of Medicine, University of Vermont, Burlington, Vermont, USA.
  • Anderson JD; Department of Otolaryngology, Stem Cell Program, University of California, Davis, Davis, California, USA.
  • Borràs FE; REMAR-IVECAT Group, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, and Nephrology Service, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Bussolati B; Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
  • Carter DRF; Department of Biological and Medical Sciences, Oxford Brookes University, Oxford, UK.
  • Dominici M; Department of Medical and Surgical Sciences of Children and Adults, University Hospital of Modena, Modena, Italy.
  • Falcón-Pérez JM; Exosomes Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Derio, Spain; Centro de Investigación Biomédica en Red de enfermedades hepáticas y digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; IKERBASQUE, Basqu
  • Gimona M; GMP Unit and EV-TT Transfer Center, Spinal Cord Injury & Tissue Regeneration Center Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.
  • Hill AF; La Trobe Institute for Molecular Science, La Trobe University, Bundoora, Australia.
  • Hoffman AM; School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • de Kleijn D; Department of Vascular Surgery, University Medical Center Utrecht and Netherlands Heart Institute, Utrecht, the Netherlands.
  • Levine BL; Center for Cellular Immunotherapies at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Lim R; Department of Obstetrics and Gynaecology, Hudson Institute of Medical Research, Monash University and The Ritchie Centre, Melbourne, Australia.
  • Lötvall J; Krefting Research Centre, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.
  • Mitsialis SA; Department of Pediatrics, Harvard Medical School and Boston Children's Hospital, Boston, Massachusetts, USA.
  • Monguió-Tortajada M; ICREC Research Program, Health Science Research Institute Germans Trias i Pujol (IGTP), Can Ruti Campus, and Cardiology Service, Germans Trias i Pujol University Hospital, Badalona, Spain.
  • Muraca M; Department of Women's and Children's Health, University of Padua, Padua, Italy.
  • Nieuwland R; Laboratory of Experimental Clinical Chemistry, Department of Clinical Chemistry and Vesicle Observation Center, Amsterdam UMC, Location AMC, University of Amsterdam, Amsterdam, the Netherlands.
  • Nowocin A; Biotherapeutics, National Institute for Biological Standards and Control (NIBSC), Medicines and Healthcare Products Regulatory Agency, Hertfordshire, UK.
  • O'Driscoll L; School of Pharmacy and Pharmaceutical Sciences and Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin, Ireland.
  • Ortiz LA; Department of Environmental and Occupational Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Phinney DG; Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida, USA.
  • Reischl I; Federal Office for Safety in Health Care (BASG) and Austrian Agency for Health and Food Safety (AGES), Institute Surveillance, Vienna, Austria.
  • Rohde E; Department of Transfusion Medicine, University Hospital, Salzburger Landeskliniken GesmbH (SALK), Salzburg, Austria; GMP Unit, Spinal Cord Injury & Tissue Regeneration Centre Salzburg (SCI-TReCS), Paracelsus Medical University (PMU), Salzburg, Austria.
  • Sanzenbacher R; Section Tissue Engineering and Cell Therapeutics, Paul-Ehrlich-Institut, Federal Institute for Vaccines and Biomedicines, Langen, Germany.
  • Théry C; Institut Curie/INSERM U932/PSL Research University, Paris, France.
  • Toh WS; Faculty of Dentistry, National University of Singapore, Singapore.
  • Witwer KW; Department of Molecular and Comparative Pathobiology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Electronic address: kwitwer1@jhmi.edu.
  • Lim SK; Institute of Molecular and Cellular Biology, Agency for Science, Technology and Research, Singapore. Electronic address: Lim_Sai_Kiang@imcb.a-star.edu.sg.
  • Giebel B; Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany. Electronic address: bernd.giebel@uk-essen.de.
Cytotherapy ; 22(9): 482-485, 2020 09.
Article em En | MEDLINE | ID: mdl-32425691
STATEMENT: The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytokine storm, exerting regenerative effects or delivering drugs, pending the generation of appropriate manufacturing and quality control provisions, pre-clinical safety and efficacy data, rational clinical trial design and proper regulatory oversight.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Mesenquimais / Vesículas Extracelulares Limite: Humans Idioma: En Revista: Cytotherapy Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Células-Tronco Mesenquimais / Vesículas Extracelulares Limite: Humans Idioma: En Revista: Cytotherapy Ano de publicação: 2020 Tipo de documento: Article